Kopran Share Price Today (KOPRAN)
TODAY IN ONE LINE
With a market cap of ₹965.71 Cr., it trades at a P/E of 38.28. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Kopran flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Strong Price MomentumRobust returns of 68.6% over 1Y
- ●Steady Dividend YieldReliable 1.59% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 71.9% YoY
- ●Sales ContractionQuarterly sales dropped 3.0% YoY
- ●Poor Capital ReturnsLow ROE of 4.8%
- ●Rising Receivables vs SalesReceivables grew 18.4% outpacing sales growth of 2.4%
Latest Kopran News
What changed recently?
Recent events, corporate actions, and announcements.
Kopran Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Kopran Limited, framed against the sector median so the premium or discount is obvious at a glance.
Kopran Limited trades at a P/E of 38.28× and P/B of 1.86×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Kopran Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Kopran Limited — derived from the live tape, not yesterday's close.
Kopran Limited last traded at ₹206.27 with an intraday range of ₹194.05–₹219 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹206.27| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 268.73 | +62.46 | +30.28% |
| R3 | 243.78 | +37.51 | +18.18% |
| R2 | 231.39 | +25.12 | +12.18% |
| R1 | 218.83 | +12.56 | +6.09% |
| PIVOT | 206.44 | 0.17 | 0.08% |
| CURRENT | 206.27 | — | — |
| S1 | 193.88 | -12.39 | -6.01% |
| S2 | 181.49 | -24.78 | -12.01% |
| S3 | 168.93 | -37.34 | -18.10% |
| S4 | 143.98 | -62.29 | -30.20% |
KOPRAN is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹–₹
Trading Above opening range, showing Bullishness
Kopran Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Kopran Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Kopran Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹965.71 Cr. and reported EPS of ₹3.41.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 630 | 681 ▲ 8.2% |
| Sales Growth YoY %Derived | 2.44% | 8.23% |
| Other Income | 4 | 0 ▼ 91.3% |
| Total Income | 634 | 682 ▲ 7.6% |
| 405 | 439 ▲ 8.5% | |
| Gross ProfitDerived | 225 | 242 ▲ 7.7% |
| Gross Margin %Derived | 35.73% | 35.57% |
| 152 | 180 ▲ 18.7% | |
| EBITDA (Operating Profit)Derived | 73 | 62 ▼ 15.0% |
| OPM %Derived | 11.58% | 9.09% |
| 25 | 28 ▲ 12.1% | |
| Profit Before Tax (PBT) | 52 | 34 ▼ 33.9% |
| 13 | 9 ▼ 35.6% | |
| Effective Tax %Derived | 25.79% | 25.10% |
| Total Profit for Period | 39 | 26 ▼ 33.3% |
| Net Profit (Owner's PAT)Derived | 39 | 26 ▼ 33.3% |
| Net Profit Margin %Derived | 6.12% | 3.78% |
| PAT Growth YoY %Derived | -24.34% | -33.26% |
| Earnings Per Share (EPS ₹) | 7.98 | 5.33 ▼ 33.2% |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 1 ▲ 165.2% |
| Total Expenses (incl. D&A & Interest) | 582 | 647 ▲ 11.3% |
| Material Cost % of RevenueDerived | 63.69% | 63.28% |
| Employee Cost % of RevenueDerived | 9.61% | 9.57% |
| Other Cost % of RevenueDerived | 14.54% | 16.91% |
| Interest Coverage (x)Derived | 6.14x | 4.25x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 315 | 358 ▲ 13.7% | 359 ▲ 0.4% | 492 ▲ 36.8% | 478 ▼ 2.9% | 551 ▲ 15.4% | 615 ▲ 11.5% | 630 ▲ 2.4% | 681 ▲ 8.2% | |
| Sales Growth YoY %Derived | — | 13.72% | 0.45% | 36.81% | -2.91% | 15.38% | 11.54% | 2.44% | 8.23% | |
| Other Income | 10 | 3 ▼ 68.1% | 1 ▼ 79.4% | 18 ▲ 2751.9% | 11 ▼ 41.0% | 3 ▼ 71.1% | 15 ▲ 376.7% | 4 ▼ 72.7% | 0 ▼ 91.3% | |
| Total Income | 324 | 361 ▲ 11.3% | 360 ▼ 0.2% | 510 ▲ 41.6% | 488 ▼ 4.3% | 554 ▲ 13.5% | 629 ▲ 13.6% | 634 ▲ 0.7% | 682 ▲ 7.6% | |
188 | 208 ▲ 10.6% | 210 ▲ 1.0% | 302 ▲ 43.7% | 271 ▼ 10.1% | 359 ▲ 32.1% | 402 ▲ 12.1% | 405 ▲ 0.7% | 439 ▲ 8.5% | ||
| Gross ProfitDerived | 127 | 150 ▲ 18.4% | 149 ▼ 0.3% | 190 ▲ 27.1% | 206 ▲ 8.5% | 192 ▼ 6.7% | 213 ▲ 10.5% | 225 ▲ 5.8% | 242 ▲ 7.7% | |
| Gross Margin %Derived | 40.24% | 41.89% | 41.58% | 38.64% | 43.17% | 34.92% | 34.60% | 35.73% | 35.57% | |
96 | 104 ▲ 7.6% | 103 ▼ 0.8% | 108 ▲ 5.3% | 119 ▲ 9.7% | 141 ▲ 18.4% | 138 ▼ 1.7% | 152 ▲ 10.0% | 180 ▲ 18.7% | ||
| EBITDA (Operating Profit)Derived | 30 | 46 ▲ 52.4% | 47 ▲ 0.8% | 82 ▲ 75.1% | 87 ▲ 6.9% | 52 ▼ 40.7% | 74 ▲ 43.7% | 73 ▼ 2.0% | 62 ▼ 15.0% | |
| OPM %Derived | 9.66% | 12.95% | 12.99% | 16.63% | 18.30% | 9.40% | 12.11% | 11.58% | 9.09% | |
17 | 18 ▲ 3.6% | 18 ▲ 1.2% | 16 ▼ 8.4% | 16 ▼ 1.3% | 19 ▲ 15.9% | 21 ▲ 14.3% | 25 ▲ 16.1% | 28 ▲ 12.1% | ||
| Profit Before Tax (PBT) | 23 | 32 ▲ 38.4% | 28 ▼ 10.7% | 83 ▲ 194.6% | 82 ▼ 1.9% | 36 ▼ 55.9% | 68 ▲ 87.3% | 52 ▼ 23.1% | 34 ▼ 33.9% | |
2 | 8 ▲ 218.4% | 7 ▼ 4.9% | 22 ▲ 199.2% | 21 ▼ 4.5% | 9 ▼ 57.4% | 17 ▲ 87.8% | 13 ▼ 19.2% | 9 ▼ 35.6% | ||
| Effective Tax %Derived | 10.48% | 24.13% | 25.68% | 26.07% | 25.37% | 24.49% | 24.56% | 25.79% | 25.10% | |
| Total Profit for Period | 20 | 24 ▲ 17.3% | 21 ▼ 12.5% | 62 ▲ 193.1% | 61 ▼ 0.9% | 27 ▼ 55.4% | 51 ▲ 87.1% | 39 ▼ 24.3% | 26 ▼ 33.3% | |
| Net Profit (Owner's PAT)Derived | 20 | 24 ▲ 17.3% | 21 ▼ 12.5% | 62 ▲ 193.1% | 61 ▼ 0.9% | 27 ▼ 55.4% | 51 ▲ 87.1% | 39 ▼ 24.3% | 26 ▼ 33.3% | |
| Net Profit Margin %Derived | 6.51% | 6.71% | 5.85% | 12.53% | 12.78% | 4.94% | 8.29% | 6.12% | 3.78% | |
| PAT Growth YoY %Derived | — | 17.26% | -12.50% | 193.08% | -0.93% | -55.38% | 87.11% | -24.34% | -33.26% | |
| Earnings Per Share (EPS ₹) | 4.74 | 5.55 ▲ 17.1% | 4.86 ▼ 12.4% | 14.24 ▲ 193.0% | 12.66 ▼ 11.1% | 5.65 ▼ 55.4% | 10.57 ▲ 87.1% | 7.98 ▼ 24.5% | 5.33 ▼ 33.2% | |
| Diluted Shares Outstanding (Cr) | 4 | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▼ 0.0% | 5 ▲ 11.5% | 5 ▲ 0.0% | 5 ▲ 0.0% | 5 ▲ 0.2% | 5 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 523.7% | 0 ▲ 172.1% | 0 ▲ 23.5% | 0 ▼ 47.5% | 0 ▲ 156.8% | 0 ▼ 32.9% | -1 ▼ 485.7% | 1 ▲ 165.2% | |
| Total Expenses (incl. D&A & Interest) | 301 | 329 ▲ 9.2% | 332 ▲ 0.8% | 426 ▲ 28.5% | 406 ▼ 4.7% | 518 ▲ 27.5% | 562 ▲ 8.4% | 582 ▲ 3.6% | 647 ▲ 11.3% | |
| Material Cost % of RevenueDerived | 55.98% | 54.82% | 62.05% | 53.97% | 62.27% | 58.37% | 64.25% | 63.69% | 63.28% | |
| Employee Cost % of RevenueDerived | 10.24% | 10.37% | 10.25% | 7.56% | 9.06% | 9.06% | 8.51% | 9.61% | 9.57% | |
| Other Cost % of RevenueDerived | 20.34% | 18.58% | 18.34% | 14.45% | 15.81% | 16.46% | 13.99% | 14.54% | 16.91% | |
| Interest Coverage (x)Derived | 2.55x | 4.18x | 4.17x | 11.47x | 14.91x | 6.42x | 7.16x | 6.14x | 4.25x |
Kopran segment analysis : revenue and profit mix.
Disclosed business segments at Kopran with their share of revenue and profit, switchable between consolidated and standalone reporting.
Kopran discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Kopran Limited.
Our AI distills the core fundamental drivers supporting Kopran Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Kopran Limited's investment case rests on 7 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Kopran Ltd exhibits a relatively low debt-to-equity ratio of 0.29, suggesting a manageable debt burden and a strong financial foundation for future growth and investment opportunities. This indicates a healthy balance sheet.
Despite recent quarterly profit variability, Kopran's promoter holding remains consistently high at approximately 44%, demonstrating significant confidence in the company's long-term prospects and potential for future value appreciation.
The company shows a positive return on equity (ROE) of 7.64%, indicating that Kopran Ltd is efficiently utilizing shareholder investments to generate profits. This is a key indicator of profitability and efficiency.
Kopran's operating profit margin (OPM) stands at a healthy 10.50%, suggesting efficient cost management and strong pricing power within its pharmaceutical industry. This demonstrates operational strength.
The pharmaceutical industry, where Kopran operates, is experiencing robust growth driven by increasing global healthcare expenditure and an aging population, presenting significant market expansion opportunities.
Key Risks.
Kopran Ltd's quarterly profit has shown significant volatility, with a substantial -32.90% decrease in the most recent quarter. This needs further investigation to understand the underlying causes and potential future impact.
The recent stock price has experienced considerable fluctuation, falling from a 52-week high of ₹327 to a low of ₹154. This volatility presents a risk for investors seeking stability in their portfolios.
Kopran's relatively low Return on Capital Employed (ROCE) of 9.75% suggests that the company might not be utilizing its capital as efficiently as some of its competitors in the pharmaceutical sector. This warrants further analysis.
The company reported a quarterly sales decline of -3.03%, indicating potential challenges in revenue generation and market demand. This trend requires close monitoring for sustained performance.
The Price-to-Earnings (PE) ratio of 22.90, while not excessively high, warrants comparison to industry peers to accurately assess if it reflects the company's growth potential and future earnings.
Flip Conditions.
Valuation risk. a P/E above 50 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Kopran Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Kopran Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Kopran Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Kopran Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Kopran Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Kopran Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Kopran Limited stood at 27.3% of traded volume, against a 20-day average of 39.8%.
Kopran announcements: results, concalls, ratings, M&A.
Filings Kopran sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Kopran files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 53 documents below.
Record Date
Kopran Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Aug-2026.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Kopran Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Appointment
Kopran Limited has informed the Exchange regarding Appointment of Mr. Vijay L Thange as Chief Technical Officer of the company w.e.f. Jun 26, 2026.
Trading Window
Kopran Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Outcome of Board Meeting
Kopran Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Investor decks & rating reports.
Kopran dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Kopran has declared, sequenced by announce and record date.
Kopran corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Kopran insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Kopran as reported to SEBI — buying and selling signals from the people who know the business best.
Kopran insider activity below tracks 2 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Mridula Somani | Insider | 18 Dec 2024 | buy | +17.65 L | — | — |
| Mridula Somani | Insider | 18 Dec 2024 | buy | +17.65 L | — | — |
About Kopran Limited: business, sector, key facts.
What Kopran Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Kopran Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: KOPRAN, BSE: 524280.
Kopran Limited is an integrated pharmaceutical company with a long history, established in 1958 and headquartered in Mumbai, India. Its core business revolves around the manufacturing and marketing of both Active Pharmaceutical Ingredients (APIs) and finished dosage forms of pharmaceuticals. This encompasses a broad range of products distributed both domestically within India and internationally.
The company's product portfolio is extensive and diverse, covering numerous therapeutic categories. Their finished dosage forms include a variety of common pharmaceutical presentations such as tablets, capsules, syrups, dry powders, suspensions, and injectables. These forms are utilized to deliver medications across a wide spectrum of therapeutic areas.
Kopran offers both branded and generic formulations of drugs. The therapeutic areas covered by their products are substantial, including but not limited to: macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, anti-acne medications, anti-infectives, anti-thrombotics, antidiabetics, pain management medications, neuromodulators, gastroenterology drugs, and cardiovascular medications. Furthermore, their offerings extend to drugs for erectile dysfunction, antiallergics, respiratory medications, oncology drugs, central nervous system medications, antiprotozoals, anthelmintics, antipeptic ulcer and gut medications, and various other therapeutic categories.
In summary, Kopran Limited operates as a fully integrated pharmaceutical company, encompassing API production and the manufacturing and marketing of a wide range of finished dosage forms across numerous therapeutic areas. Their long history and diverse product portfolio establish them as a significant player in the Indian and international pharmaceutical markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Kopran Limited (KOPRAN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Kopran Limited (KOPRAN)?
The current share price of Kopran Limited (KOPRAN) is ₹206.27. Today, the stock has gained by ₹12.69 (6.56%), trading in a range of ₹194.05 to ₹219. The stock opened at ₹194.5 with a trading volume of 38,54,785 shares.
02Is Kopran Limited stock a good investment for long-term?
Kopran Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹965.71 crores, P/E ratio of 38.28, ROE of 4.85%, and ROCE of 9.75%. The dividend yield stands at 1.59%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Kopran Limited stock?
The 52-week high price of Kopran Limited (KOPRAN) is ₹219, while the 52-week low is ₹107. Currently trading at ₹206.27, the stock is 88.6% away from its 52-week low and 5.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Kopran Limited stock at the current price?
Whether to buy Kopran Limited stock at ₹206.27 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.28 and P/B ratio of 1.86. Today's performance shows a gain of 6.56%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Kopran Limited and when is the next dividend?
Kopran Limited offers a dividend yield of 1.59%, which means for every ₹100 invested at the current price of ₹206.27, you can expect to receive approximately ₹1.59 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Kopran Limited?
Kopran Limited's key financial metrics include: P/E Ratio: 38.28, P/B Ratio: 1.86, ROE: 4.85%, ROCE: 9.75%, Dividend Yield: 1.59%, EPS: ₹3.41, Book Value: ₹107.35, and Debt-to-Equity: 0.29. The company's market cap stands at ₹965.71 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Kopran Limited stock performing today in the market?
Kopran Limited stock opened at ₹194.5 and is currently trading at ₹206.27, showing a gain of ₹12.69 (6.56%). The intraday high is ₹219 and low is ₹194.05. The trading volume stands at 38,54,785 shares, indicating strong market participation today.
08What is the P/E ratio of Kopran Limited and what does it indicate?
Kopran Limited has a Price-to-Earnings (P/E) ratio of 38.28, which means investors are willing to pay ₹38.28 for every ₹1 of earnings. With an EPS of ₹3.41, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Kopran Limited (KOPRAN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.